Prostate Cancer–Specific Mortality After Radical Prostatectomy for Patients Treated in the Prostate-Specific Antigen Era | Zendy

Andrew J. Stephenson | Zendy; Michael W. Kattan | Zendy; James A. Eastham | Zendy; Fernando J. Bianco | Zendy; Ofer Yossepowitch | Zendy; Andrew J. Vickers | Zendy; Eric A. Klein | Zendy; David P. Wood | Zendy; Peter T. Scardino | Zendy

Open Access

Prostate Cancer–Specific Mortality After Radical Prostatectomy for Patients Treated in the Prostate-Specific Antigen Era

Author(s) -

Andrew J. Stephenson,

Michael W. Kattan,

James A. Eastham,

Fernando J. Bianco,

Ofer Yossepowitch,

Andrew J. Vickers,

Eric A. Klein,

David P. Wood,

Peter T. Scardino

Publication year - 2009

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2008.18.2501

Subject(s) - medicine , prostatectomy , prostate cancer , prostate specific antigen , prostate , urology , cancer , oncology

The long-term risk of prostate cancer-specific mortality (PCSM) after radical prostatectomy is poorly defined for patients treated in the era of widespread prostate-specific antigen (PSA) screening. Models that predict the risk of PCSM are needed for patient counseling and clinical trial design.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research